Technical Analysis for ACOR - Acorda Therapeutics, Inc.

Grade Last Price % Change Price Change
B 6.7 5.18% 0.33
ACOR closed up 5.18 percent on Friday, January 15, 2021, on 42 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Up
Historical ACOR trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
New 52 Week Closing High Bullish 5.18%
Jack-in-the-Box Bullish Bullish Swing Setup 5.18%
Spinning Top Other 5.18%
Upper Bollinger Band Walk Strength 5.18%
Inside Day Range Contraction 5.18%
Older End-of-Day Signals for ACOR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Acorda Therapeutics, Inc. Description

Acorda Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other central nervous system disorders primarily in the United States. Its products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; and Zanaflex Capsules and Zanaflex tablets (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The company also markets products for the improvement of walking in adult patients with MS under the Fampyra name internationally. In addition, it is developing Diazapam Nasal Spray, which is in NDA preparations for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase II clinical trials for cerebral palsy and post-stroke deficits; AC105, which is in Phase II clinical trials for the treatment of SCI and TBI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for SCI. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Antibodies Autoimmune Diseases Injury Chloride Clinical Trial Spas Heart Failure Multiple Sclerosis Nervous System Disorders Central Nervous System Disorders Stroke Potassium DSL Spinal Cord Seizure Nasal Spray Seizures Spinal Cord Injury Treatment Of Heart Failure Spasticity Tbi Acorda Therapeutics Treatment Of Ms Zanaflex

Is ACOR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 7.18
52 Week Low 0.4224
Average Volume 3,400,526
200-Day Moving Average 0.96
50-Day Moving Average 1.56
20-Day Moving Average 2.74
10-Day Moving Average 4.75
Average True Range 0.52
ADX 60.82
+DI 63.16
-DI 1.23
Chandelier Exit (Long, 3 ATRs ) 5.63
Chandelier Exit (Short, 3 ATRs ) 2.21
Upper Bollinger Band 7.06
Lower Bollinger Band -1.58
Percent B (%b) 0.96
BandWidth 315.34
MACD Line 1.37
MACD Signal Line 0.91
MACD Histogram 0.4561
Fundamentals Value
Market Cap 381.04 Million
Num Shares 56.9 Million
EPS 1.02
Price-to-Earnings (P/E) Ratio 6.56
Price-to-Sales 0.23
Price-to-Book 0.14
PEG Ratio 0.51
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.67
Resistance 3 (R3) 7.56 7.14 7.50
Resistance 2 (R2) 7.14 6.90 7.19 7.45
Resistance 1 (R1) 6.92 6.74 7.03 7.02 7.40
Pivot Point 6.50 6.50 6.55 6.55 6.50
Support 1 (S1) 6.28 6.25 6.39 6.38 6.00
Support 2 (S2) 5.86 6.10 5.91 5.95
Support 3 (S3) 5.63 5.86 5.90
Support 4 (S4) 5.73